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Babesiosis is a tickborne disease caused by Babesia microti, an 
intracellular parasite of red blood cells. Presently, B. microti is the most 
common and deadly pathogen transmitted by blood transfusion. B. 
microti infects humans via Ixodes scapularis ticks, the same vector that 
carries Borrelia burgdorferi, the causative agent of Lyme disease. Co-
infection with these two diseases increases the duration and severity of 
symptoms, posing a major therapeutic challenge. We aimed to determine 
the co-infection rate of  B. microti in individuals who tested positive for 
Lyme disease in New York State. Of the 154 sera samples that were 
tested by immunofluorescence assay, 33 (21.4%) of the of the individuals 
who had Lyme disease and a current B. burgdorferi infection also tested 
positive for IgM and IgG antibodies against B. microti, suggesting recent 
co-infection with both TBDs. Additionally, of the individuals who previously 
had Lyme disease as indicated by IgG antibodies against B. burgdorferi, 
4 (2.6%) tested positive for antibodies against B. microti.  Only one 
individual (0.7%) in the Lyme disease negative control group was positive 
for antibodies against B. microti. The results suggests co-infection of B. 
microti and Lyme disease is prevalent in New York, an area endemic for 
TBDs. Additionally, our findings agree with reports that B. burgdorferi may 
help facilitate the emergence of B. microti. Our data suggest the need for 
an extensive study investigating co-infection of B. microti and Lyme 
disease and further support the need for an FDA-approved screening test 
to help prevent transfusion-transmitted babesiosis. 
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Figure 1. Distribution of Reported Lyme and Lyme/Babesiosis Patients 
(Source: Trends in Pathology).  Map of the United States indicating counties in 
which reported reported cases of Lyme disease and co-infection of Lyme and 
babesiosis, respectively.  Counties with three or more cases of Lyme disease but 
fewer than three cases of babesiosis are depicted in green. Counties with three or 
more cases of Lyme disease and three or more cases of babesiosis are depicted 
in gray. 
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Abstract  Hypothesis  
 
 There is a higher co-infection rate of B. microti in individuals that test  
 positive for B. burgorferi than is currently being reported in New York State. 
 
Conclusions 
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Introduction 
Human babesiosis is an emerging zoonotic TBD caused by protozoa of 
the genus Babesia, which are obligate intracellular parasites of red blood 
cells1. Babesia microti is currently the number one pathogen that is 
transmitted by blood transfusion in the U.S. for which no FDA-approved 
donor screening is currently available1. It is also responsible for the 
highest percentage (38%) of transfusion-related infectious fatalities 
reported to the FDA in transfusion recipients2.   
 
B. microti and B. burgdorferi, the causative agents of human babesiosis 
and Lyme disease respectively, are known to be prevalent within the same 
geographical range3. This is attributed to the fact that the same vector, the 
Ixodes scapularis tick, transmits both infections.  I. scapularis ticks may be 
infected with either of these pathogens or both simultaneously4. Some 
studies have suggested concurrent infection with B. burgdorferi has a 
synergistic effect on B. microti3. 
  
Reported co-infection rates of B. microti with B. burgdorferi in varies 
greatly with the focus often being on the co-infection of ticks and not 
humans4,5. Moreover, it has been suggested that co-infection with these 
two diseases, promotes the development of more severe symptoms than 
seen in patients infected with the individual pathogen; which poses a 
major therapeutic challenge6. In addition, each of these diseases are 
treated with different antibiotic regimens, specific to that parasitic disorder.  
If co-infection is not diagnosed in a patient, then only one of the diseases 
may be successfully treated, posing a risk to immunocompromised 
individuals undergoing blood transfusion. 
Table 1. Results table. Presence of Lyme disease was based on the detection of IgM (current infection) or IgG (past infection) 
antibodies or both by Western blotting.  Individuals were considered IFA positive for B. microti if they tested positive for both IgM 
and IgG antibodies. Of the 154 samples tested,  0.7% of patients tested negative for Lyme disease and positive for B. microti while 
21.4% of patients were positive for current Lyme disease and B. microti, representing a significant increase for individuals with 
current co-infection (p > 0.5).  Of the individuals who previously had Lyme disease, 2.6% of patients were also positive for B. 
microti.   
The aim of this study was to determine the co-infection rate of B. microti in individuals that tested positive for Lyme 
disease. Overall, the findings of our study suggest that additional testing for the prevalence of Babesia, in individuals 
suspected of or diagnosed with Lyme disease needs to be performed, particularly in areas where it is endemic.  
Moving forward, it would be useful to do a more extensive study with a larger sample size and well matched controls. 
The results presented in this study coincide with our hypothesis suggesting that there is a higher rate of co-infection 
than previously reported.    
 
Figure 4. Representative images of B. microti immunofluorescence assay. A 
titer of 1:32 was used to determine whether an individual was positive for 
antibodies against IgM, while a titer of 1:64 was used for IgG antibodies. A-D.  
Representative images of the negative control (A), positive control (B), positive 
individual at 1:32 dilution for IgM antibodies (C), and positive individual at 1:64 
dilution for IgG antibodies. 
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Figure 2. Sample population and demographics. A. Sample collection. Breakdown of the months in which samples (n=154) 
were collected.  Samples were collected during summer months in which tickborne diseases are most prevalent. B.  Gender 
distribution. Of the individuals tested, 58% were male, 40% were female and 2% were unknown. C. Age distribution. The median 
age of our sample population was 46.6 and our mean age was 52.  
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Figure 3. Indirect Immunofluorescence 
assay for B. microti. Immunofluorescence 
assay (IFA) was used for the detection of 
IgM and IgG classes of antibodies against 
B. microti in human sera.  
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